An Open-Label, Multicenter Phase Ib Study of The Safety and Tolerability of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab and/or Other Treatments in Patients With Solid Tumors

Phase: 
I

An Open-Label, Multicenter Phase Ib Study of The Safety and Tolerability of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab and/or Other Treatments in Patients With Solid Tumors

This purpose of this study is to evaluate the safety and tolerability of study drug atezolizumab when administered with bevacizumab and FOLFOX in patients with gastric cancer. This study will also evaluate the safety and tolerability of atezolizumab administered with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer.

Are you Eligible? (Inclusion Criteria)

Patients must have Pancreatic Cancer

Specialty Area(s)

Trial Location

Columbia University Medical Center
Herbert Irving Pavilion
161 Fort Washington Avenue, 8th Floor
New York, NY 10032
United States